NovoCure NVCR Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 75.2%-2.0pp | 74.5%-2.8pp | 75.4%-1.0pp | 76.4%+0.6pp | 77.2%+2.3pp | |
| Operating margin | -27.2%-0.4pp | -23.5%+4.7pp | -27.5%0.0pp | -27.4%+6.2pp | -26.8%+13.9pp | |
| Net margin | -25.7%+0.8pp | -20.8%+7.1pp | -27.7%-1.7pp | -27.1%+3.5pp | -26.4%+10.3pp | |
| EBITDA margin | -24.9%+0.1pp | -21.2%+5.1pp | -25.4%+0.2pp | -25.5%+6.2pp | -24.9%+13.7pp | |
| Free cash flow margin | -7.1%+4.5pp | -11.5%-0.1pp | -10.1%+3.4pp | -12.8%— | -11.6%— | |
| Returns | ||||||
| Return on equity | -50%-4.4pp | -38.9%+7.8pp | -50.6%-10.9pp | -48.1%-4.7pp | -45.5%+3.2pp | |
| Return on assets | -17%-3.1pp | -13.3%+0.8pp | -13.8%-1.1pp | -13.9%+0.3pp | -13.9%+2.9pp | |
| Return on invested capital | -65.8%-22.7pp | -58.6%-22.8pp | -148.2%-117pp | -74.9%-40.1pp | -43%-10.9pp | |
| Efficiency | ||||||
| Asset turnover | 0.7×+0.1× | 0.6×+0.1× | 0.5×0.0× | 0.5×0.0× | 0.5×+0.1× | |
| Inventory turnover | 4×+0.6× | 4.4×+0.6× | 4×+0.5× | 3.7×+0.1× | 3.5×-0.1× | |
| Liquidity | ||||||
| Current ratio | 2.9×+1.4× | 2.9×+1.4× | 1.5×+0.1× | 1.4×-5.0× | 1.5×-4.8× | |
| Quick ratio | 2.7×+1.3× | 2.7×+1.3× | 1.5×+0.1× | 1.4×-4.8× | 1.4×-4.6× | |
| Cash ratio | 0.4×+0.2× | 0.4×+0.2× | 0.4×+0.2× | 0.2×-0.8× | 0.2×-2.7× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0.2×+0.1× | 0.1×+0.1× | 0.1×+0.1× | 0.1×-1.5× | |
| Debt-to-assets | 0.1×0.0× | 0.1×0.0× | 0×0.0× | 0×0.0× | 0×-0.5× | |
| Interest coverage | -21.1×-16.6× | -8.5×-4.2× | -6.7×-3.2× | -5.6×-1.4× | -4.5×+0.6× | |
| Per Share | ||||||
| Book value per share | $2.90-11.7% | $3.05-8.6% | $3.05-8.5% | $3.13-6.8% | $3.28-2.0% | |
| Valuation | ||||||
| Market capitalization | $1.24B-36.7% | $1.45B-55.1% | $1.44B-14.2% | $1.9B+3.1% | $1.96B+16.8% | |
| Enterprise value | $1.19B-36.3% | $1.41B-54.4% | $1.15B-24.6% | $1.79B+5.6% | $1.87B+3.0% | |
| Price / sales | 1.8×-1.3× | 2.2×-3.1× | 2.2×-0.7× | 3×-0.3× | 3.2×0.0× | |
| Price / book | 3.8×-1.7× | 4.3×-4.7× | 4.2×-0.4× | 5.4×+0.3× | 5.4×+0.7× | |
| EV / sales | 1.8×-1.2× | 2.1×-3.0× | 1.8×-0.8× | 2.8×-0.2× | 3×-0.4× | |
| Free cash flow yield | -3.9%-0.2pp | -5.2%-3.1pp | -4.5%+0.1pp | -4.2%— | -3.7%— | |
| Earnings yield | -14%-5.6pp | -9.4%-4.2pp | -12.3%-3.4pp | -9%+0.2pp | -8.4%+3.1pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are NovoCure's profit margins?
- NovoCure (NVCR) runs a 75.2% gross margin and a -27.2% operating margin, with a -25.7% net margin.
- Where do NovoCure's ratios come from?
- Every ratio is computed from NovoCure's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.